)
Visual
earnings real time
INmune Bio (INMB) investor relations material
INmune Bio Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary30 Oct, 2025
Executive summary
Leadership changes in 2025 included new CEO, CFO, and Chairman appointments, with a focus on advancing CORDStrom, XPro, and INKmune platforms targeting RDEB, Alzheimer's, and oncology.
CORDStrom completed pivotal and pilot-scale manufacturing runs for RDEB, showing systemic benefit and preparing for regulatory filings in the UK, US, and EU.
XPro completed Phase 2 in Alzheimer's; while the trial did not meet primary endpoints, a biomarker-defined subgroup showed benefit, and no ARIA safety signals were observed.
INKmune completed Phase 2 in prostate cancer, meeting primary and two secondary endpoints, with final data expected Q4 2025.
All operations are reported as a single segment focused on clinical-stage biotechnology development.
Financial highlights
Net loss for Q3 2025 was $6.5M, down from $12.1M in Q3 2024; net loss for the nine months ended September 30, 2025, was $40.7M, up from $32.9M year-over-year, including a $16.5M impairment for XPro.
R&D expenses for Q3 2025 were $4.9M, down from $10.1M year-over-year; for the nine months, R&D was $18.3M, down from $25.8M.
G&A expenses for Q3 2025 were $2.5M, up from $2.2M; for the nine months, $7.1M, slightly down from $7.4M.
Cash and equivalents stood at $27.7M as of September 30, 2025.
Revenue for Q3 2025 was $50,000, up from $14,000 in Q3 2024.
Outlook and guidance
CORDStrom MAA filing in the UK expected mid-2026, with BLA filing in the US to follow; additional data to be presented in Q4 2025.
XPro end of Phase 2 meeting with FDA and MRI data anticipated in Q1 2026; further development paused pending partnership.
INKmune randomized Phase 2 trial design to be developed in 2026 as resources allow; final CARE-PC trial data expected Q4 2025.
Expects continued significant losses and negative cash flows; current cash projected to be insufficient for one year from financial statement issuance.
Plans to seek additional funding through equity, debt, partnerships, or other sources.
CORDStrom's differentiation from topical RDEB therapies?
FDA's stance on XPro's enrichment biomarkers?
INKmune's future development and partnership plan?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next INmune Bio earnings date
Q4 202527 Mar, 2026
Next INmune Bio earnings date
Q4 202527 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
INmune Bio, Inc. is a clinical-stage immunotherapy company. The company focuses on reprogramming the patient's innate immune system to treat cancer, Alzheimer's disease and non-alcoholic steatohepatitis. It has several development programs, including INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation in their blood; XPro1595 for the treatment of Alzheimer's disease; LivNate to treat patients with non-alcoholic steatohepatitis; and Quellor for cytokine release syndrome and complications of COVID-19
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage